Corbus Pharmaceuticals Holdings, Inc. is involved in the development of innovative therapeutics for the treatment of rare diseases with significant unmet medical needs. Self-described.

Corbus Pharmaceuticals Holdings, Inc.

Domain Not Resolving

DNSSEC

Microsoft

COVID-19

Microsoft Azure

Microsoft Azure US East Region

QuoteMedia

Chief Operating Officer

Craig Stuart Millian

VP & Head, Global Marketing

Brian Walsh

Vice President Quality Assurance

Jeffrey Holyoke

Risk, Safety, Compliance

Andrew Kolodziej

Director, Clinical Project Management

Anthony Piscitelli

Director, IT Operations & Security

Belkacem Abdessemed

Senior Director of Statistical Programming at Corbus Pharmaceuticals Inc.

Brian Conley

Associate Director

Daqing Wang

Head of Business Development

Dylan Wenke

Director, Investor Relations & Corporate Communications

Lindsey Smith

Dominic Smethurst

Chief Medical Officer

Robert Discordia

Yuval Cohen

Chief Executive Officer

Barbara White

Chief Medical Officer & Head of Researchv

Ed Karski

Global Head, Procurement

Sean Moran

Craig Millian

Companies that Went Public in 2014

United States Public Companies With Fewer Than 1000 Employees

Biotechnology Companies With More Than 50 Employees

United States Public Companies With Fewer Than 100 Employees

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

Post-IPO Equity - Corbus Pharmaceuticals

K2 HealthVentures

Post-IPO Debt - Corbus Pharmaceuticals

Grant - Corbus Pharmaceuticals

Cystic Fibrosis Foundation

Venture Round - Corbus Pharmaceuticals

Norwood

Massachusetts

United States

North America

Corbus Pharmaceuticals

Corbus Pharmaceuticals price target lowered by $5 at H.C. Wainwright, here's why

Corbus Pharmaceuticals price target lowered to $40 from $85 at B. Riley

Corbus Pharmaceuticals participates in a conference call with Truist

Corbus Pharmaceuticals GAAP EPS of -$0.90

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors

Corbus Pharmaceuticals initiated with bullish view at B. Riley

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors

Corbus Pharmaceuticals Board Member To Sell Shares In Planned Trading

A next-generation antibody-drug-conjugate targeting Nectin-4, used in clinical trials for treating advanced solid tumors with high Nectin-4 expression.

An anti-integrin monoclonal antibody designed to block the activation of TGFβ expressed on cancer cells, currently in clinical development.

A highly peripherally restricted CB1 inverse agonist for the treatment of obesity, with pre-clinical data presented and an IND filing planned.

Denmark

Europe

Panama

Russian Federation

Indonesia

Asia

HTML5

Apache Server

Google Fonts

Fonts.com

Adobe Fonts

Bootstrap

Modernizr

Google Analytics

Twilio

DigiCert

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

news impact assignment basic	general
public peers	general	Oct 2, 2024 12:34 PM	97f2e31c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 2, 2024 12:34 PM	6c11a1b5
crunchbase trigger	general	Nov 27, 2024 12:50 PM	f158c040
crunchbase profile	general	Nov 27, 2024 1:21 PM	b8085c25
li profile	general
translate crunchbase fundingrounds	general	Nov 27, 2024 2:00 PM	2f5831b2
peers	general	Oct 2, 2024 12:34 PM	f4d8a702
news basic	general	Oct 2, 2024 12:34 PM	cfef8016
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CORBUSPHARMA

Corbus Pharmaceuticals Holdings, Inc.

Last Close

16.73

22/11 21:00

Market Cap

550.26M

Beta: -

Volume Today

177.61K

Avg: -